The estimated Net Worth of Yadin Rozov is at least $206 Thousand dollars as of 13 March 2023. Yadin Rozov owns over 70,000 units of Oramed Pharmaceuticals, Inc stock worth over $205,870 and over the last 3 years Yadin sold ORMP stock worth over $0.
Yadin has made over 1 trades of the Oramed Pharmaceuticals, Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Yadin bought 70,000 units of ORMP stock worth $141,400 on 13 March 2023.
The largest trade Yadin's ever made was buying 70,000 units of Oramed Pharmaceuticals, Inc stock on 13 March 2023 worth over $141,400. On average, Yadin trades about 14,000 units every 0 days since 2022. As of 13 March 2023 Yadin still owns at least 86,500 units of Oramed Pharmaceuticals, Inc stock.
You can see the complete history of Yadin Rozov stock trades at the bottom of the page.
Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank, and Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: